Brown Advisory Inc. Sells 75,557 Shares of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS)

Brown Advisory Inc. cut its position in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS - Free Report) by 39.7% during the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 114,698 shares of the company's stock after selling 75,557 shares during the quarter. Brown Advisory Inc. owned about 0.07% of Xeris Biopharma worth $630,000 at the end of the most recent quarter.

Several other large investors have also recently bought and sold shares of XERS. NewEdge Advisors LLC acquired a new stake in shares of Xeris Biopharma during the fourth quarter worth approximately $34,000. Cibc World Markets Corp acquired a new position in Xeris Biopharma during the 4th quarter worth about $44,000. Raymond James Financial Inc. acquired a new position in Xeris Biopharma during the 4th quarter valued at about $45,000. Two Sigma Advisers LP bought a new stake in shares of Xeris Biopharma in the 4th quarter valued at about $47,000. Finally, Aquatic Capital Management LLC bought a new position in shares of Xeris Biopharma during the 4th quarter worth approximately $50,000. Institutional investors and hedge funds own 42.75% of the company's stock.

Wall Street Analyst Weigh In

A number of research firms have issued reports on XERS. Wall Street Zen cut Xeris Biopharma from a "buy" rating to a "hold" rating in a research report on Thursday, May 22nd. Oppenheimer boosted their price objective on Xeris Biopharma from $6.00 to $7.00 and gave the company an "outperform" rating in a report on Friday, May 9th. Two analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. According to MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus target price of $6.25.

Insider Activity at Xeris Biopharma

In other news, insider Kevin Mcculloch acquired 25,000 shares of Xeris Biopharma stock in a transaction dated Friday, June 13th. The shares were purchased at an average cost of $4.38 per share, for a total transaction of $109,500.00. Following the transaction, the insider owned 1,708,585 shares of the company's stock, valued at $7,483,602.30. This trade represents a 1.48% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through the SEC website. Company insiders own 6.47% of the company's stock.

Xeris Biopharma Stock Down 0.6%

XERS traded down $0.03 during trading on Wednesday, reaching $5.26. 2,057,875 shares of the company were exchanged, compared to its average volume of 2,068,456. The company has a market cap of $822.56 million, a price-to-earnings ratio of -17.53 and a beta of 0.66. The company's 50-day moving average is $4.79 and its two-hundred day moving average is $4.34. Xeris Biopharma Holdings, Inc. has a 12-month low of $2.10 and a 12-month high of $6.07.

Xeris Biopharma (NASDAQ:XERS - Get Free Report) last announced its earnings results on Thursday, May 8th. The company reported ($0.06) earnings per share for the quarter, topping analysts' consensus estimates of ($0.07) by $0.01. The business had revenue of $57.80 million during the quarter, compared to the consensus estimate of $57.61 million. Equities analysts forecast that Xeris Biopharma Holdings, Inc. will post -0.41 earnings per share for the current year.

About Xeris Biopharma

Xeris Biopharma Holdings, Inc, a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome.